Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-29 21:13:08 - browse：85673

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD podcast: mifepristone case, GLP

WSS

Abortion pill case raises question: who can sue the FDA?

Apple Vision Pro: A first look at health apps on the new VR headset

SAMSHA loosens regulations on methadone treatment centers

Readout Newsletter: Merck, Vertex, and Viking updates

Do digital therapeutics have a future in medicine?

Apple Vision Pro: A first look at health apps on the new VR headset

hotspot

Wikipedia

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Washington mulls new rules to avert another Change Healthcare

Anesthesiologist group: stop taking Ozempic before surgery

Commercial surrogacy can be ethical, despite pope’s claims

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: mifepristone case, GLP

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: mifepristone case, GLP

United colonoscopy coverage change 'may cost lives,' doctors say

Covid misinformation case heads to Supreme Court

focus

States should stop sabotaging methadone treatment reform

Time to name cancers by genetics, not organ of origin, expert says

ARCH Venture Partners is raising $3 billion for a life sciences fund

Even great ERs can’t make up for American health disparities

Novo Nordisk to expand supply of Wegovy for U.S. patients

FDA drug safety: Singulair case shows systemic surveillance flaws

focus

leisure time

focus

focus